Sygnature Discovery is one of North America's largest contract research organizations (CROs) specializing in integrated drug discovery. The company offers a wide range of services in the drug discovery phase, including target validation, hit identification, hit-to-lead, lead optimization, and ADMET prediction. Their expertise covers many therapeutic areas such as oncology, neuroscience, respiratory, and anti-infectives, among others. Sygnature Discovery provides services like DMPK consultancy, computer-aided drug design, and in vivo pharmacology, leveraging advanced bioscience knowledge, medicinal chemistry, and structural biology to support drug candidates through preclinical and clinical development. With a collaborative approach and a track record of success, Sygnature Discovery enables clients to efficiently bring drug candidates from discovery to clinical development.
Medicinal Chemistry; synthetic chemistry; drug discovery • In vitro Bioscience • Computational Chemistry & Informatics • DMPK & Physical sciences • Protein crystallography
501 - 1000 employees
Founded 2011
💊 Pharmaceuticals
🧬 Biotechnology
🔬 Science
💰 Secondary Market on 2021-06
November 27
Seeking Business Development Director to sell Sygnature’s discovery solutions in Boston. Focus on establishing business partnerships for growth in North America.